Why IMU is a multi multi bagger, page-25901

Hawkbar33, thank you for the January 2023 article researched from Nature Medicine, published just before Imugene licenced azer-cel in August 2023.

Interesting quote from Memorial Sloan Kettering Cancer Center (MSK) "Dr. Mailankody says Allogene and other companies are working to develop even more effective allogeneic CAR T cells. “We don’t know yet if we will be using this exact version of the CAR T cells in the future,” he says. “But this concept of knocking down CD52 and TRAC in order to give allogeneic CAR T cells has applications beyond multiple myeloma that could benefit other blood cancers, and even some solid tumors.”

Imugene shareholders and the FDA will have published azer-cel data results before the end of the year, with a video discussing the azer-cel results from Leslie Chong, together with Paul Woodard and Bradley Glover.

Regards.